These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 18559761

  • 1. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.
    Quereux G, Marques S, Nguyen JM, Bedane C, D'incan M, Dereure O, Puzenat E, Claudy A, Martin L, Joly P, Delaunay M, Beylot-Barry M, Vabres P, Celerier P, Sasolas B, Grange F, Khammari A, Dreno B.
    Arch Dermatol; 2008 Jun; 144(6):727-33. PubMed ID: 18559761
    [Abstract] [Full Text] [Related]

  • 2. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012.
    Dummer R, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, Morris S, Weichenthal M, Stadler R, Bagot M, Cozzio A, Bernengo MG, Knobler R.
    J Clin Oncol; 2012 Nov 20; 30(33):4091-7. PubMed ID: 23045580
    [Abstract] [Full Text] [Related]

  • 3. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
    Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, Knopf B, Koch HJ, Hauschild A.
    Cancer; 2003 Sep 01; 98(5):993-1001. PubMed ID: 12942567
    [Abstract] [Full Text] [Related]

  • 4. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.
    Br J Dermatol; 2009 Jun 01; 160(6):1299-307. PubMed ID: 19222457
    [Abstract] [Full Text] [Related]

  • 5. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G, North-Eastern German Society of Gynecological Oncology.
    Cancer Chemother Pharmacol; 2009 Aug 01; 64(3):585-91. PubMed ID: 19156414
    [Abstract] [Full Text] [Related]

  • 6. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study.
    Di Lorenzo G, Di Trolio R, Montesarchio V, Palmieri G, Nappa P, Delfino M, De Placido S, Dezube BJ.
    Cancer; 2008 Mar 01; 112(5):1147-52. PubMed ID: 18098221
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP, Levitan D, Fleischer AB.
    J Dermatolog Treat; 2009 Mar 01; 20(3):169-76. PubMed ID: 19016373
    [Abstract] [Full Text] [Related]

  • 8. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M.
    J Clin Oncol; 2007 Jul 20; 25(21):3109-15. PubMed ID: 17577020
    [Abstract] [Full Text] [Related]

  • 9. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Worldwide Bexarotene Study Group.
    Arch Dermatol; 2001 May 20; 137(5):581-93. PubMed ID: 11346336
    [Abstract] [Full Text] [Related]

  • 10. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.
    Eur J Haematol; 2007 Apr 20; 78(4):297-302. PubMed ID: 17286608
    [Abstract] [Full Text] [Related]

  • 11. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R.
    J Am Acad Dermatol; 2003 Jul 20; 49(1):35-49. PubMed ID: 12833006
    [Abstract] [Full Text] [Related]

  • 12. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma.
    Hau P, Fabel K, Baumgart U, Rümmele P, Grauer O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel C, Hübner F, Jauch T, Drechsel E, Kleiter I, Wismeth C, Zellner A, Brawanski A, Steinbrecher A, Marienhagen J, Bogdahn U.
    Cancer; 2004 Mar 15; 100(6):1199-207. PubMed ID: 15022287
    [Abstract] [Full Text] [Related]

  • 13. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J, Caelyx/Kaposi's Sarcoma Spanish Group.
    Clin Infect Dis; 2008 Aug 01; 47(3):410-7. PubMed ID: 18582203
    [Abstract] [Full Text] [Related]

  • 14. Pegylated Liposomal Doxorubicin HCL (Caelyx) in combination with Sandostatin LAR as salvage therapy in patients with small-cell lung cancer.
    Charpidou A, Hatzidarellis EP, Alamara C, Dilana K, Pantazopoulos K, Kotteas E, Georgatou N, Syrigos KN.
    In Vivo; 2006 Aug 01; 20(4):553-7. PubMed ID: 16900789
    [Abstract] [Full Text] [Related]

  • 15. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
    Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH.
    J Clin Oncol; 2010 Oct 10; 28(29):4485-91. PubMed ID: 20697094
    [Abstract] [Full Text] [Related]

  • 16. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA, Mitchell T, Ferreira S, Seed PT, Russell-Jones R, Calonje E, Whittaker SJ.
    Br J Dermatol; 2006 Oct 10; 155(4):756-62. PubMed ID: 16965425
    [Abstract] [Full Text] [Related]

  • 17. Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.
    Funk A, Hensley F, Krempien R, Neuhof D, Van Kampen M, Treiber M, Roeder F, Timke C, Herfarth K, Helmbold P, Debus J, Bischof M.
    Eur J Dermatol; 2008 Oct 10; 18(3):308-12. PubMed ID: 18474461
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.
    Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Bettacchi A, Mulattieri S, Picardi P, Tassetti A, Scortechini AR, Fioritoni G, Leoni P.
    Eur J Haematol; 2009 Mar 10; 82(3):184-93. PubMed ID: 19215609
    [Abstract] [Full Text] [Related]

  • 19. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
    de Quatrebarbes J, Estève E, Bagot M, Bernard P, Beylot-Barry M, Delaunay M, D'Incan M, Souteyrand P, Vaillant L, Cordel N, Courville P, Joly P.
    Arch Dermatol; 2005 Sep 10; 141(9):1117-20. PubMed ID: 16172308
    [Abstract] [Full Text] [Related]

  • 20. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R.
    Oncologist; 2007 Oct 10; 12(10):1247-52. PubMed ID: 17962618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.